$891.54
Value $265B
GS and HIT stock compared: price, dividend, valuation and results, from SEC filings.
$891.54
Value $265B
$0.33
Value $18M
Goldman Sachs (GS) has a market value of $265B and Health In Tech (HIT) $18M. Over the last year, with dividends, GS moved +11.4% and HIT -78.4%. Dividend yield: GS 2.02%, HIT none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
GS$265B
HIT$18M
GS is 14,365 times HIT
Revenue, 12 months
GS$69.7B
HIT$31M
GS is 2,254 times HIT
Net income, 12 months
GS$22.2B
HIT-$11M
Operating margin
GS–
HIT–
ROIC
GS11.3%
HIT-67.4%
78.7 points apart
P/E
GS12.4
HIT–
Dividend yield
GS2.0%
HIT0.0%
2.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
GS+11.4%
HIT-78.4%
| Period | GSWith dividends | HITWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +11.4%Price +9.2% | -78.4%Price -78.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
GSGoldman SachsHITHealth In Tech
| Price | $891.54 | $0.33 |
|---|---|---|
| Market value | $265B | $18M |
| Enterprise value (EV) | – | $15M |
| P/E | 12.4 | – |
| P/E, 5-year median | 14.1 | – |
| P/B | 2.4 | 1.4 |
| EV/EBIT | – | – |
| Free cash flow yield | – | – |
| Revenue, 12 months | $69.7B | $31M |
|---|---|---|
| Net income, 12 months | $22.2B | -$11M |
| Free cash flow, 12 months | – | – |
| Earnings per share, 12 months | $69.53 | -$0.19 |
| Revenue growth, year on year | 8.9% | 71.0% |
| Revenue growth a year, past | +5.5%over 5 years | +31.9%over 2 years |
| EPS growth a year, past | +15.7%over 5 years | +100.0%over 1 years |
| Gross margin | – | 50.5% |
|---|---|---|
| Operating margin | – | – |
| Net margin | 31.8% | -37.1% |
| ROIC | 11.3% | -67.4% |
| ROE | 17.9% | -64.9% |
| Cash | $455B | $10M |
|---|---|---|
| Total debt | $389B | $6.7M |
| Net debt / EBITDA | – | – |
| Interest cover | – | – |
| Dividend yield | 2.0% | – |
|---|---|---|
| Dividend per share, 12 months | $18.00 | – |
| Dividend growth a year, past | +22.9%over 5 years | – |
| Buyback yield | 4.7% | – |
| Shareholder yield | 6.7% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Goldman Sachs ($265B) is about 14,365.1 times Health In Tech ($18M), at today's prices.
Since November 12, 2025, GS's price moved +9.2% and HIT's -78.4%. With dividends: GS +11.4% (+11.4% a year), HIT -78.4% (-78.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.02% for Goldman Sachs and none for Health In Tech. Over the last twelve months they paid $18.00 and – per share.
Over the last twelve months, the net margin was 31.8% for Goldman Sachs and -37.1% for Health In Tech, and the operating margin – and –. Revenue was $69.7B and $31M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.